论文部分内容阅读
笔者收集了经内镇证实伴幽门螺杆菌(HP)感染的消化性溃疡140例。随机分为三组,分别使用呋喃唑酮+得乐冲剂+雷尼替丁(F+CBS+R组),呋喃唑酮+得乐冲剂(F+CBS组),及单用雷尼替丁(R组).疗程4周,维持治疗4周。通过近期及一年的随访的治疗效果,其溃疡4周治愈率以F+CBS+R组最高(97.6%,82/84),显著高于F+CBS组(75%,27/36)和R组(70%,14/20)(P<0.01).HP消失率和胃粘膜炎症病理好转主是F+CBS+R组(81%,52.4%)和F+CBS组(80.6%,52.8%)显著高于R组(5%,10%)(P<0.001).停药一年随访结果,溃疡复发率是F+CBS+R组(13.1%,11/84)和F+CBS组(15.2%,5/33)显著低于R组(16.7%,12/18)(P<0.001);HP根除率与溃疡复发率相对应,前两组(83.8%,82.8%)明显高于R组(P<0.001).作者认为联合使用清除HP药物(F,CBS)、制酸药物(H2受体拮抗剂)和胃粘膜保护剂(CBS),不仅可有效地提高消化性质疡的近期疗效,而且可以显著降低其复发率。
I collected by the town confirmed with Helicobacter pylori (HP) infection of peptic ulcer 140 cases. The rats were randomly divided into three groups: Furazolidone + Detox + Ranitidine (F + CBS + R), Furazolidone + Detox (F + CBS) and Ranitidine alone (R). Treatment for 4 weeks, maintenance treatment for 4 weeks. The four-week cure rate of ulcer with F + CBS + R group was the highest (97.6%, 82/84), which was significantly higher than that of F + CBS group (75%, 27/36) and R group %, 14/20) (P <0.01). The rate of disappearance and gastric mucosal inflammation were significantly higher in F + CBS + R group (81%, 52.4%) and F + CBS group (80.6%, 52.8%) than in R group (5%, 10% <0.001). The one-year follow-up results showed that the ulcer recurrence rate was significantly lower in the F + CBS + R group (13.1%, 11/84) and F + CBS group (15.2%, 5/33) ) (P <0.001). The eradication rate of HP corresponded with the recurrence rate of ulcer. The former two groups (83.8%, 82.8%) were significantly higher than those in R group (P <0.001). The authors conclude that combined use of Clenbuterol (F, CBS), antacid (H2 receptor antagonist) and gastric mucosal protective agent (CBS) not only improves the short-term curative effect of digestive ulcer effectively but also significantly reduces its recurrence rate.